OncoMax addressed the 27th Annual Congress of the European Association of Urologists (EAU), that took place in Paris on February 24-28 with the results of its studies in the field of oncolological urological diseases.
The results of efficacy studies for various dosages of medicine OM-RCA-01, monoclonal humanized antibody blocking the fibroblast growth factor receptor 1 (FGFR1), which was developed by OncoMax for treatment of renal cell carcinoma, were presented at the special meeting “Renal Tumour – Fundamental Studies”. The meeting was opened by such famous scientists as professor E. Oosterwijk (the Netherlands) and Dr. T. Klatte (Austria). In the review they highlighted 3 of the most interesting projects, and among them they mentioned the report made by the Scientific Director of OncoMax, I.V. Tsimafeyeu.
Dr. T. Klatte also mentioned that the target chosen by the Russian researchers is pathogenically significant: “Development of a medicine based on the anti-FGFR1 antibody which blocks the fundamentally new target on the renal carcinoma cells is very interesting and important”.
The report demonstrated that monoclonal antibody OM-RCA-01 selectively blocks the targeted receptor, which in its turn causes inhibition of tumour growth in the course of experiments using cell lines and laboratory animals. Moreover, demonstration of therapeutic activity of the antibody even in small concentrations arouse interest of Prof. E. Oosterwijk, as this is the peculiarity which differs the medicine from already existing ones, for example anti-VEGF(R) inhibitors which demonstrate dependence of its efficacy from dosage. The Chairmen of the meeting expressed hope that the development of monoclonal antibody OM-RCA-01 will be continued in the course of Phase I of clinical trials.